$3.04 Billion Opportunity in Biosimilar Bevacizumab Market by 2032 Market Overview
Biosimilar bevacizumab is a biological product highly like the reference biologic Avastin. It is used to treat various types of cancer, including colorectal, lung, breast, kidney, and ovarian cancer. The biosimilar market for bevacizumab has witnessed significant growth due to the increasing prevalence of cancer, the high cost of the reference product, and the growing acceptance...
0 Shares
13 Views
0 Reviews